Author pages are created from data sourced from our academic publisher partnerships and public sources.
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
ABSTRACT Induction of broadly cross-reactive neutralizing antibodies is a high priority for AIDS vaccine development but one that has proven difficult to be achieved. While most immunogens generate… Expand
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Building Better Vaccines In the past few years, several highly potent, broadly neutralizing antibodies (bNAbs) specific for the gp120 envelope protein of HIV-1 have been discovered. The goal of this… Expand
Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection
ABSTRACT The characterization of the cross-reactive, or heterologous, neutralizing antibody responses developed during human immunodeficiency virus type 1 (HIV-1) infection and the identification of… Expand
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies
- A. McGuire, Sam Hoot, +9 authors L. Stamatatos
- Biology, Medicine
- The Journal of experimental medicine
- 8 April 2013
Eliminating key glycosylation sites on HIV envelope (Env) restores binding of the germline versions of known broadly neutralizing anti-Env antibodies.
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Most existing viral vaccines generate antibodies that either block initial infection or help eradicate the virus before it can cause disease. For HIV-1, obstacles to eliciting protective neutralizing… Expand
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice
A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs) that can prevent infection, but it has not yet been possible to elicit these antibodies by immunization.… Expand
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
Abstract Antibody responses develop following SARS-CoV-2 infection, but little is known about their epitope specificities, clonality, binding affinities, epitopes and neutralizing activity. We… Expand
Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
- I. Mikell, D. Sather, S. Kalams, M. Altfeld, G. Alter, L. Stamatatos
- Biology, Medicine
- PLoS pathogens
- 1 January 2011
Recent cross-sectional analyses of HIV-1+ plasmas have indicated that broadly cross-reactive neutralizing antibody responses are developed by 10%–30% of HIV-1+ subjects. The timing of the initial… Expand
An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades
ABSTRACT SF162 is a primary (PR), non-syncytium-inducing, macrophagetropic human immunodeficiency virus type 1 (HIV-1) clade B isolate which is resistant to antibody-mediated neutralization. Deletion… Expand
Human immunodeficiency viruses.
- E. Barker, S. Barnett, L. Stamatatos, J. Levy
- IARC monographs on the evaluation of carcinogenic…
In the early 1980s, the appearance of skin lesions characterized by a bluish-purple discoloration in young homosexual men was noted by physicians in cities on both the East and West coasts of the… Expand